Mirvaso and Pregnancy
When Mirvaso (brimonidine gel) was given to pregnant animals by mouth, it did not appear to cause birth defects. Although the potential risks to humans are not fully known, it is believed that Mirvaso does not appear to be particularly dangerous when used during pregnancy. However, talk to your healthcare provider about the best rosacea treatment for your individual situation.
Mirvaso® (brimonidine gel) is a prescription skin medication used for the treatment of rosacea. Based on information from animal studies, this drug does not appear to be particularly dangerous during pregnancy, although the possible risks to humans are largely unknown at this time.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Mirvaso is classified as a pregnancy Category B medicine.
Pregnancy Category B is given to medicines that have not been adequately studied in pregnant humans but do not appear to cause harm to the fetus in animal studies. Medications that have been shown to be safe for use in pregnancy in humans but have caused problems in laboratory animals are also given a Category B rating.
In studies, when high doses of brimonidine (the active ingredient in Mirvaso) were given to pregnant animals by mouth, it did not appear to cause birth defects.
However, it is important to note that animals do not always respond to medicines in the same way that humans do. Therefore, a pregnancy Category B medicine should be given to a pregnant woman only if her healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child.
If you are pregnant or thinking of becoming pregnant while using Mirvaso, let your healthcare provider know. He or she will consider the benefits and risks before making a recommendation in your particular situation. If you are struggling with rosacea during pregnancy, ask your healthcare provider for suggestions for safe and effective treatment strategies.